Johnson & Johnson (NYSE:JNJ) will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.
Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.02 per share, down from $2.29 per share in the year-ago period. Johnson & Johnson projects to report revenue of $22.45 billion for the recent quarter, compared to $21.39 billion a year earlier, according to data from Benzinga Pro.
Johnson & Johnson has secured FDA approval for expanded use of its Spravato nasal spray, now cleared as a standalone treatment for adults with major depressive disorder who failed at least two oral antidepressants. Previously, it was only approved with oral antidepressants for treatment-resistant depression.
Johnson & Johnson shares gained 0.8% to close at $148.15 on Tuesday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- B of A Securities analyst Tim Anderson maintained a Neutral rating and cut the price target from $166 to $160 on Jan. 17, 2025. This analyst has an accuracy rate of 64%.
- Citigroup analyst Joanne Wuensch maintained a Buy rating and cut the price target from $185 to $175 on Dec. 11, 2024. This analyst has an accuracy rate of 76%.
- Guggenheim analyst Vamil Diwan maintained a Neutral rating and raised the price target from $156 to $162 on Nov. 6, 2024. This analyst has an accuracy rate of 75%.
- Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and raised the price target from $163 to $166 on Oct. 16, 2024. This analyst has an accuracy rate of 72%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $169 to $175 on Oct. 16, 2024. This analyst has an accuracy rate of 65%.
Considering buying JNJ stock? Here’s what analysts think:
Read This Next:
